Dr. Rana's research focuses on the pathogenesis of preeclampsia, a common hypertensive disorder of pregnancy. She is particularly
interested in elucidating the role of angiogenic biomarkers in the prediction of adverse maternal and fetal outcomes. Dr. Rana conducts national and international translational studies.
Harvard School of Public Health
Boston
MPH - Clinical Effectiveness
2015
WIHRI, Brown University
Providence
- MFM Fellowship
2008
University of Chicago
Chicago
- Residency OB/GYN
2005
Mayo Clinic
Rochester
- Residency General Surgery
2001
Jawaharlal Nehru Medical College
India
MD - Residency Ob/GYN
1999
Jawaharlal Nehru Medical College
India
MBBS - Medicine
1996
Effect of postpartum oral furosemide use on postpartum readmissions and blood pressure trends.
Effect of postpartum oral furosemide use on postpartum readmissions and blood pressure trends. Pregnancy Hypertens. 2025 Mar; 39:101199.
PMID: 39884048
A 26-Year-Old Woman with Postpartum Abdominal Pain.
A 26-Year-Old Woman with Postpartum Abdominal Pain. NEJM Evid. 2025 Feb; 4(2):EVIDmr2400398.
PMID: 39873543
Neonatal cost savings in hypertensive disorders of pregnancy: Economic evaluation of the sFlt-1/PlGF test with real world implementation of biomarkers.
Neonatal cost savings in hypertensive disorders of pregnancy: Economic evaluation of the sFlt-1/PlGF test with real world implementation of biomarkers. Pregnancy Hypertens. 2025 Mar; 39:101190.
PMID: 39826331
Response to the Letter to the Editor: "Signs or symptoms of suspected preeclampsia - A retrospective National database study of prevalence, costs, and outcomes".
Response to the Letter to the Editor: "Signs or symptoms of suspected preeclampsia - A retrospective National database study of prevalence, costs, and outcomes". Pregnancy Hypertens. 2025 Mar; 39:101183.
PMID: 39798448
Systematic treatment and management of postpartum hypertension using remote patient monitoring.
Systematic treatment and management of postpartum hypertension using remote patient monitoring. Pregnancy Hypertens. 2025 Mar; 39:101180.
PMID: 39709789
Real-world evidence for utility of serum angiogenic and antiangiogenic biomarker testing.
Real-world evidence for utility of serum angiogenic and antiangiogenic biomarker testing. Am J Obstet Gynecol. 2025 Feb; 232(2):e71.
PMID: 39278342
Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor testing.
Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor testing. Am J Obstet Gynecol. 2025 Feb; 232(2):e67.
PMID: 39128768
Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy.
Real-world evidence for the utility of serum soluble fms-like tyrosine kinase 1/placental growth factor test for routine clinical evaluation of hospitalized women with hypertensive disorders of pregnancy. Am J Obstet Gynecol. 2025 Apr; 232(4):385.e1-385.e21.
PMID: 39029547
Patient perceptions of remote patient monitoring program for hypertensive disorders of pregnancy.
Patient perceptions of remote patient monitoring program for hypertensive disorders of pregnancy. Arch Gynecol Obstet. 2024 09; 310(3):1563-1576.
PMID: 38977439
Extended postpartum outcomes with systematic treatment of and management of postpartum hypertension program.
Extended postpartum outcomes with systematic treatment of and management of postpartum hypertension program. Pregnancy Hypertens. 2024 Sep; 37:101138.
PMID: 38878602